Royalty Pharma plc (RPRX) FY2025 Annual Balance Sheet

Income StatementCash FlowBalance Sheet

Balance Sheet

As of 2025-12-31

Swipe to see the full flow
Royalty Pharma plc (RPRX) FY2025 Annual Balance SheetBalance sheet as of 2025-12-31. The chart shows assets, liabilities and equity at that date.Current liabilities$636.21 MCurrent assets$1.53 BLiabilities$9.91 BAssets$19.62 BNon-current liabilities$9.27 BNon-current assets$18.09 BEquity$9.71 BGross equity(calculated)$9.72 BHOLDINGSASSET CLASSASSETSCLAIM CLASSCLAIM SUB-CLASSCLAIMSFinancial royalty assetsCash and cash equivalentsOther royalty income receivableAvailable for sale debt securitiesOther current assetsFinancial royalty assets, netGoodwillAvailable for sale debt securitiesEquity method investmentsEquity securitiesOther assetsCurrent portion of long-term debtInterest payableDistributions payable to legacy non-controlling interestsOther current liabilitiesAccounts payable and accrued expensesLong-term debtAccrued compensation liabilitiesOther liabilitiesAdditional paid-in capitalRetained earningsCommon stock - Class R Redeemable SharesCommon stock - Class A Ordinary SharesNon-controlling interestsCurrent assetsNon-current assetsAssetsCurrent liabilitiesNon-current liabilitiesLiabilitiesEquityGross equity (calculated)Treasury interestsCurrent portion of long-term debtCurrent portion of long-term debt$380.00 MFinancial royalty assetsFinancial royalty assets$854.39 MInterest payableInterest payable$110.82 MCash and cash equivalentsCash and cash equivalents$618.70 MCurrent liabilitiesCurrent liabilities$636.21 MCurrent assetsCurrent assets$1.53 BDistributions payable to legacy non-controlling interestsDistributions payable to legacynon-controlling interests$72.83 MOther royalty income receivableOther royalty income receivable$29.32 MLiabilitiesLiabilities$9.91 BOther current liabilitiesOther current liabilities$53.16 MAvailable for sale debt securitiesAvailable for sale debt securities$18.80 MAssetsAssets$19.62 BAccounts payable and accrued expensesAccounts payable and accrued expenses$19.40 MOther current assetsOther current assets$6.89 MNon-current liabilitiesNon-current liabilities$9.27 BLong-term debtLong-term debt$8.57 BNon-current assetsNon-current assets$18.09 BFinancial royalty assets, netFinancial royalty assets, net$16.21 BEquityEquity$9.71 BAccrued compensation liabilitiesAccrued compensation liabilities$577.87 MOther liabilitiesOther liabilities$120.84 MGross equity (calculated)Gross equity(calculated)$9.72 BAdditional paid-in capitalAdditional paid-in capital$4.12 BGoodwillGoodwill$924.63 MRetained earningsRetained earnings$2.36 BAvailable for sale debt securitiesAvailable for sale debt securities$419.00 MCommon stock - Class R Redeemable SharesCommon stock - Class R Redeemable Shares$63.00 KEquity method investmentsEquity method investments$289.97 MCommon stock - Class A Ordinary SharesCommon stock - Class A Ordinary Shares$43.00 KEquity securitiesEquity securities$171.31 MNon-controlling interestsNon-controlling interests$3.24 BOther assetsOther assets$79.29 MTreasury interestsTreasury interests−$2.61 M
Chart details

Royalty Pharma plc (RPRX) FY2025 Annual Balance Sheet

Balance sheet as of 2025-12-31. The chart shows assets, liabilities and equity at that date.

Assets
19,620,780,000 US dollars
Current assets
1,528,091,000 US dollars
Non-current assets
18,092,689,000 US dollars
Liabilities
9,905,841,000 US dollars
Current liabilities
636,211,000 US dollars
Non-current liabilities
9,269,630,000 US dollars
Equity
9,714,939,000 US dollars
Noncontrolling interest
3,238,039,000 US dollars. Included in consolidated equity; this amount is not added again.
Financial royalty assets
854,386,000 US dollars
Cash and cash equivalents
618,696,000 US dollars
Other royalty income receivable
29,316,000 US dollars
Available for sale debt securities
18,800,000 US dollars
Other current assets
6,893,000 US dollars
Financial royalty assets, net
16,208,482,000 US dollars
Goodwill
924,634,000 US dollars
Available for sale debt securities
419,000,000 US dollars
Equity method investments
289,968,000 US dollars
Equity securities
171,312,000 US dollars
Other assets
79,293,000 US dollars
Current portion of long-term debt
380,000,000 US dollars
Interest payable
110,818,000 US dollars
Distributions payable to legacy non-controlling interests
72,825,000 US dollars
Other current liabilities
53,164,000 US dollars
Accounts payable and accrued expenses
19,404,000 US dollars
Long-term debt
8,570,917,000 US dollars
Accrued compensation liabilities
577,870,000 US dollars
Other liabilities
120,843,000 US dollars
Additional paid-in capital
4,123,088,000 US dollars
Retained earnings
2,356,318,000 US dollars
Common stock - Class R Redeemable Shares
63,000 US dollars
Common stock - Class A Ordinary Shares
43,000 US dollars
Deferred shares, $0.000001 par value; issued and outstanding: 2025–411,475 and 2024–392,255
0 US dollars
Common stock - Class B Ordinary Shares
0 US dollars
Non-controlling interests
3,238,039,000 US dollars
Treasury interests
negative 2,612,000 US dollars
Gross equity (calculated)
9,717,551,000 US dollars. Net equity plus the magnitudes of its negative contributions equals gross positive equity. The negative contributions enter this reconciliation as add-backs; their filed signs stay negative.

Chart connections

  • Assets equal liabilities plus consolidated equity. Consolidated equity includes noncontrolling interests when reported.
  • Treasury shares and other negative equity contributions reduce equity.
Royalty Pharma plc (RPRX) FY2025 Annual Balance Sheet Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!